IDEXX LABORATORIES INC /DE Cost of Revenue
IDEXX LABORATORIES INC /DE (IDXX) reported Cost of Revenue of $437.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE cost of goods and services sold for the quarter ending 2026-06-30 was $437.50M, a 5.49% increase year-over-year.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for the quarter ending 2026-03-31 was $418.08M, a 11.47% increase year-over-year.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for the quarter ending 2025-12-31 was $432.46M, a 12.73% increase year-over-year.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for the quarter ending 2025-09-30 was $421.88M, a 11.17% increase year-over-year.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for fiscal 2025 was $1.64B, a 8.27% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for fiscal 2024 was $1.52B, a 3.24% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for fiscal 2023 was $1.47B, a 7.92% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE cost of goods and services sold for fiscal 2022 was $1.36B.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $437.50M 10-Q · filed 2026-08-04 | $855.58M 10-Q · filed 2026-08-04 | $1.29B derived: sum of 3 quarters · filed 2026-08-04 | $1.71B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $418.08M 10-Q · filed 2026-05-05 | $850.55M derived: sum of 2 quarters · filed 2026-05-05 | $1.27B derived: sum of 3 quarters · filed 2026-05-05 | $1.69B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $432.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $854.35M derived: sum of 2 quarters · filed 2026-02-20 | $1.27B derived: sum of 3 quarters · filed 2026-08-04 | $1.64B 10-K · filed 2026-02-20 |
| 2025-09-30 | $421.88M 10-Q · filed 2025-11-03 | $836.61M derived: sum of 2 quarters · filed 2026-08-04 | $1.21B 10-Q · filed 2025-11-03 | $1.60B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $414.73M 10-Q · filed 2026-08-04 | $789.77M 10-Q · filed 2026-08-04 | $1.17B derived: sum of 3 quarters · filed 2026-08-04 | $1.55B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $375.05M 10-Q · filed 2026-05-05 | $758.68M derived: sum of 2 quarters · filed 2026-05-05 | $1.14B derived: sum of 3 quarters · filed 2026-05-05 | $1.52B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $383.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $763.13M derived: sum of 2 quarters · filed 2026-02-20 | $1.15B derived: sum of 3 quarters · filed 2026-02-20 | $1.52B 10-K · filed 2026-02-20 |
| 2024-09-30 | $379.50M 10-Q · filed 2025-11-03 | $763.92M derived: sum of 2 quarters · filed 2025-11-03 | $1.13B 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $384.42M 10-Q · filed 2025-08-04 | $755.44M 10-Q · filed 2025-08-04 | ||
| 2023-12-31 | $1.47B 10-K · filed 2026-02-20 | |||
| 2022-12-31 | $1.36B 10-K · filed 2025-02-21 | |||
| 2021-09-30 | $337.50M 10-Q · filed 2021-11-02 | $674.33M derived: sum of 2 quarters · filed 2021-11-02 | $981.26M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $336.83M 10-Q · filed 2021-07-30 | $643.76M 10-Q · filed 2021-07-30 | ||
| 2021-03-31 | $306.93M 10-Q · filed 2021-05-04 | |||
| 2020-09-30 | $299.18M 10-Q · filed 2021-11-02 | $557.43M derived: sum of 2 quarters · filed 2021-11-02 | $824.18M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $258.25M 10-Q · filed 2021-07-30 | $525.00M 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $266.75M 10-Q · filed 2021-05-04 | |||
| 2019-09-30 | $260.35M 10-Q · filed 2020-10-29 | $522.60M derived: sum of 2 quarters · filed 2020-10-29 | $767.06M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $262.25M 10-Q · filed 2020-07-31 | $506.71M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $244.46M 10-Q · filed 2020-04-30 | |||
| 2018-09-30 | $239.81M 10-Q · filed 2019-10-31 | $488.12M derived: sum of 2 quarters · filed 2019-10-31 | $722.67M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $248.31M 10-Q · filed 2019-08-01 | $482.87M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $234.56M 10-Q · filed 2019-05-01 | |||
| 2017-09-30 | $217.97M 10-Q · filed 2018-11-01 | $638.03M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |